Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials

AIM: To assess the lipid‐lowering efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in people with hypercholesterolaemia and prediabetes at baseline vs people with normoglycaemia at baseline in a pooled analysis of 10 ODYSSEY phase III trials. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Leiter, L. A., Müller‐Wieland, D., Baccara‐Dinet, M. T., Letierce, A., Samuel, R., Cariou, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763418/
https://www.ncbi.nlm.nih.gov/pubmed/28799203
http://dx.doi.org/10.1111/dme.13450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763418/
https://www.ncbi.nlm.nih.gov/pubmed/28799203
http://dx.doi.org/10.1111/dme.13450

Ejemplares similares